Corrigendum to "Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity" [Mol Metab 78 (2023) 101801].

Autor: Friedrichsen MH; Novo Nordisk A/S, Søborg, Denmark. Electronic address: mfrc@novonordisk.com., Endahl L; Novo Nordisk A/S, Søborg, Denmark., Kreiner FF; Novo Nordisk A/S, Søborg, Denmark., Goldwater R; Parexel International, Baltimore, MD, USA., Kankam M; Altasciences Clinical Kansas, Overland Park, KS, USA., Toubro S; Novo Nordisk A/S, Søborg, Denmark., Nygård SB; Novo Nordisk A/S, Søborg, Denmark.

Publikováno v: Molecular metabolism [Mol Metab] 2024 Nov; Vol. 89, pp. 102023. Date of Electronic Publication: 2024 Sep 05.

Prevalence of Baseline Cardiac Arrhythmias in Participants with Overweight or Obesity in Phase 1 Clinical Trials: Analysis of 24-Hour Holter Electrocardiogram Recordings.

Autor: Skovgaard D; Novo Nordisk A/S, Søborg, Denmark., Haahr PM; Novo Nordisk A/S, Søborg, Denmark., Lester R; Celerion, Tempe, Arizona, USA., Clark K; Celerion, Tempe, Arizona, USA., Paglialunga S; Celerion, Tempe, Arizona, USA., Finer N; Novo Nordisk A/S, Søborg, Denmark., Friedrichsen MH; Novo Nordisk A/S, Søborg, Denmark., Hjerpsted JB; Novo Nordisk A/S, Målev, Denmark., Engelmann MDM; Novo Nordisk A/S, Søborg, Denmark.

Publikováno v: Journal of clinical pharmacology [J Clin Pharmacol] 2023 May; Vol. 63 (5), pp. 539-543. Date of Electronic Publication: 2023 Jan 20.